Abstract 1855P
Background
Cancer is one of the most common causes of mortality & morbidity globally, and the diagnosis of cancer is a stressful event causing significant psychological distresses, most commonly depression and anxiety, directly interfering with disease outcome and quality of life.
Methods
This cross-sectional type of descriptive study was conducted at the National Institute of Cancer Research & Hospital (NICRH), Dhaka for a period of 12 months. Sample size was 405 using purposive sampling. Data were collected from the patients through face-to-face interviews using a semi-structured questionnaire and Bangla version of the DASS-21 scale.
Results
In this study, the mean age of the respondents was 47.4 ± 16.5 years, predominantly male. Gastrointestinal cancers (27.4%) were most prevalent, followed by lung cancer (19.5%). The prevalence of depressive and anxious symptomatology was 38.02% and 42.96%, respectively. More than half (53.3%) of the patients were suffering from either of depression and/or anxiety. Table: 1855P
Severity | Depression | Anxiety |
Mild | 19.7% | 17.3% |
Moderate | 13.6% | 11.6% |
Severe | 3.7% | 9.4% |
Extremely Severe | 1% | 4.7% |
In inpatient setting, depressive disorders were significantly higher in females than males (p<0.01) and among the lung cancer patients; in contrast, gastrointestinal cancer and the presence of co-morbidities predisposed more to anxiety (p<0.05). Although mode of treatment and severity of disease showed no significant relationship with the prevalence of depression or anxiety, ECOG performance status was found to have significant impact on both of the disorders. On analysis of the socio-demographic variables, illiterate and low-income people were seen to suffer more with a severe and extremely severe level of depression, on the other hand, homemakers and lower socio-economic class had higher levels of anxiety.
Conclusions
The study findings showed a higher prevalence of depression and anxiety in the inpatient setting; therefore, counseling, screening, and timely evaluation of mental health should be a part of the standard protocol of oncology care.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1878P - Prevalence of burnout in GU oncologists in central Asia: BUCARE survey
Presenter: Oxana Shatkovskaya
Session: Poster session 05
1879P - Investigating the effect of family support on the mental health of patients with breast cancer
Presenter: Maryam Garousi
Session: Poster session 05
1880P - Cancer care: Psychoeducational intervention for first-year residents of a general hospital in northeastern Mexico
Presenter: Celia Beatriz Gonzalez-Alcorta
Session: Poster session 05
1991P - Safety and effectiveness of surgery or radiotherapy after PD-L1 Inhibitor (TQB-2450) and chemotherapy induction therapy in patients with limited-stage small cell lung cancer: A phase II trial
Presenter: Fenghuan Sun
Session: Poster session 05
1992P - A phase II safety and efficacy study of PM8002 (anti-PD-L1 x VEGF-A bispecific) combined with paclitaxel as a second-line therapy for small cell lung cancer (SCLC)
Presenter: Ying Cheng
Session: Poster session 05
1993P - Phase IIIb study of durvalumab plus platinum–etoposide in first-line treatment of extensive-stage small cell lung cancer (CANTABRICO): Safety results
Presenter: Maria Dolores Isla Casado
Session: Poster session 05
1994P - Carboplatin, etoposide, bevacizumab, and atezolizumab in patients with extensive-stage SCLC – GOIRC-01-2019 CeLEBrATE ML41241 trial
Presenter: Karim Rihawi
Session: Poster session 05
1995P - Long-term benefit of atezolizumab plus chemotherapy in extensive stage small cell lung cancer (ES-SCLC): Exploratory analysis from the IMfirst study
Presenter: Maria Rosario Garcia Campelo
Session: Poster session 05
1996P - The impact of an etoposide shortage on patients with extensive-stage small cell lung cancer (ES-SCLC): Results of a natural experiment
Presenter: Claire Browne
Session: Poster session 05
1997P - A study of sintilimab combined with anlotinib and chemotherapy as second-line or later therapy in extensive-disease small cell lung cancer
Presenter: Zhe-Hai Wang
Session: Poster session 05